Magmaris® RMS

Confirmed clinical safety and,
efficacy*, fast Magnesium
resorption and
better deliverability.

Find out more
Magmaris® RMS

Procedure

Experience shows1 that following the 4 Ps implantation strategy for
Magmaris may lead to better patient outcomes.

Find out more
Procedure

Clinically Proven

Magmaris’ clinical body of evidence keeps growing with new data from BIOSOLVE-IV

Find out more
Clinically Proven

Find out how Magmaris can benefit your daily practice

CONTACT US
magmaris TLF

Clinical Study Highlights

BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris Resorbable Magnesium Scaffold2

BIOSOLVE-IV: Magmaris Scaffold Performs Well in Real World Settings Even in More Complex Patient Groups

Find out more
News At a Glance

EuroPCR 2022: Magmaris RMS Confirms High Safety Profile at
3 years with BIOSOLVE-IV

READ ARTICLE

TCT 2022:BIOSOLVE-IV Full-Cohort Two-Year Data Confirm Excellent Safety and Efficacy Profile of Magmaris RMS

READ ARTICLE

Future of Resorbable Scaffolds Looks Rosier

READ ARTICLE
NewsRoom

*Based on BIOSOLVE-II, -II/-III and -IV, for patient populations see study details;
1. According to the Magnesium 2,000 program; 2. Bennett J. Safety and Efficacy of the Resorbable Magnesium Scaffold, Magmaris in a Real-World Setting – 24-month Follow-up of the Full Cohort (2066 subjects) of the BIOSOLVE-IV Registry. Presented at: TCT, September 2022, Boston, USA. ClinicalTrials.gov: NCT02817802


Magmaris is a trademark or registered trademark of the BIOTRONIK Group of Companies.
​​​​​​​Magmaris is currently not available in the US.

© 2022 BIOTRONIK AG – All rights reserved.
Specifications are subject to modification, revision and improvement.